Oceana, Urigen deal

The companies mutually ended a 2009 deal that gave Oceana a right of first refusal to license all indications of Urigen's URG101 that may be approved by FDA. Under the terms of the original agreement, Oceana was to assist Urigen in preparing for a Phase II meeting with the agency regarding URG101 and pay up to $50,000 in fees to Urigen's consultants in connection with the meeting. ...